We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Otsuka is among the top 5 pharma companies from Japan, with strong global drug development and commercial capabilities in CNS disorders, kidney diseases and oncology.
Otsuka aspires to be your strong partner in the CNS and renal space. Our antipsychotic franchise around aripiprazoe and brexpiprazole (Abilify, Rexulti) has made us a global leader in mental health. Based on tolvaptan's recent FDA approval for polycycstic kidney disease (Jynarque for ADPKD), we are now aspiring to become a leader in the renal disease space. We are now searching for opportunities to complement our pipeline with innovative therapeutic solutions to clear unmet needs in psychiatric, neurological and renal disorders - regardless of modality (small molecule, biologic, allogeneic cell therapy, gene therapy or digital therapeutics).